- Two types of T cells. T cells can be either “effector” or “regulatory”. EpiVax tests for both types.
EpiVax offers access to in vitro and in vivo immunogenicity screening assays. In vitro assays: Peptide binding assays: HLA binding assays can be used to assess whether peptides derived from protein sequences (usually following a first-pass immunoinformatics analysis) can bind to either MHC class I or class II. In vitro assays using human blood cells: EpiVax also offers access to FACS-based, ELISA and ELISpot assays for detecting T cell responses to protein drugs. HLA Transgenic mice: Immunogenicity preductions conducted using human T-cell epitope mapping tools are tested in murine models that are transgenic for (express) human HLA. EpiVax offers access to a number of transgenic mouse strains that express the most common HLA A, HLA B and HLA DR molecules. T cell responses in these mice correlate directly with T cell responses observed in infected/vaccinated humans. Comparisions of immunogenicity can be done to a high degree of accuracy in the mouse model for selected HLA class II alleles (HLA DR 0101, 0301, 0401, 1501).
T cell response drives B cell response - in this example we show how B cell response to Flu is dependent on T cell response to antibodies in the HA molecule.
